APA (7th ed.) Citation

A, Q., S, L., MS, D., L, B., Z, M., O, B., . . . V, L. (2025). Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: Primary results of a French multicentre observational study (NAOS). Annals of hematology, 104(8), 4175. https://doi.org/10.1007/s00277-025-06498-5

Chicago Style (17th ed.) Citation

A, Quinquenel, et al. "Real-world Efficacy and Safety Outcomes of Acalabrutinib in Chronic Lymphocytic Leukemia: Primary Results of a French Multicentre Observational Study (NAOS)." Annals of Hematology 104, no. 8 (2025): 4175. https://doi.org/10.1007/s00277-025-06498-5.

MLA (9th ed.) Citation

A, Quinquenel, et al. "Real-world Efficacy and Safety Outcomes of Acalabrutinib in Chronic Lymphocytic Leukemia: Primary Results of a French Multicentre Observational Study (NAOS)." Annals of Hematology, vol. 104, no. 8, 2025, p. 4175, https://doi.org/10.1007/s00277-025-06498-5.